Skip to main content

Table 1 HIF-1/2 and downstream target inhibitor drugs and clinical efficacy

From: Mechanisms of HIF-driven immunosuppression in tumour microenvironment

Drug

Target

Mechanism of inhibition

Tumour

Ref.

Acriflavine

HIF-1

Prevents HIF-1α/HIF-1β dimerization

Prostate and colorectal cancer

[91, 95]

Anthracyclines

HIF-1

Inhibits HIF-1 transcriptional activity

Hepatocellular carcinoma, prostate cancer

[92]

Cardenolides

Breast cancer

[96]

PT2385

HIF-2

Disrupts HIF-2α/ARNT heterodimerization and inhibits HIF-2α target gene expression

Clear cell renal cell carcinoma

[93]

MK-6482

[94]

Benzopyranyl triazole

HIF-1

Increases HIF-1α hydroxylation and subsequent HIF-1α protein degradation

Used in combination with EGFR inhibitor gefitinib in lung and breast cancer

[97]

BIX01294 at low dosage

Hepatocellular carcinoma

[98]

IDF-1174

HIF-1

Increases HIF-1α protein degradation

Hepatocellular carcinoma, colorectal carcinoma

[99]

LBH589

Diffuse large B-cell lymphoma, Hodgkin lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer and NSCLC

[99]

MPT0G157

Colorectal cancer

[100]

Vorinostat

HIF-1, HIF-2

Decreases HIF-1/2α translation/nuclear localization/stability, increases HIF-1/2 degradation

Hepatocellular carcinoma

[99]

Trastuzumab (Herceptin)

HIF-1 targets

Target oncogenic growth factor signalling pathways regulated by HIF-1

Breast cancer

[24]

Imatinib

Gastric gastrointestinal stromal tumours

Galunisertib

HIF-1 targets

TGFβRI kinase inhibitor

Breast, colon, lung cancers, and hepatocellular carcinoma

[24]

Lenvatinib

HIF-1 targets

VEGF inhibitor

Hepatocellular carcinoma

[101]

SCH58261

HIF-1/2 targets

A2AR antagonist; inhibits immunosuppressive adenosine in TME

Head and neck squamous cell carcinoma

[102]